Abstract 1783P
Background
ADT+ dct has been a standard of care first-line for hvHSPC patients (pt). We hypothesized that early addition of ipi and/or nivo could improve outcomes.
Methods
PROSTRATEGY was designed as a seamless randomized (2/1/1) multi-arm multi-stage trial, to compare ADT+dct (75 mg/m2 x6 cycles) vs ADT+dct→nivo (3 mg/Kg/2w x 12 mo), or ADT+ipi+dct→nivo (ADT + ipi 1 mg/Kg/3w x 2 cycles → dct x3 cycles → ipi 3mg/Kg/3w x2 cycles → dct x3 cycles → nivo x 12 mo) in hvHSPCa pt in 30 academic centers in Spain. The aims of the pilot phase were to check ffeasibility, safety and efficacy outcomes in terms of radiographic and PSA response, radiographic and clinical progression-free survival or death (rPFS, cPFS), time to castration-resistant prostate cancer or death (TCRPC), time to symptomatic skeletal-related event (TSSRE) and overall survival (OS) from the first dose of ADT, based on both RECIST1.1 + PCWG3 and iRECIST ( Seymour, Lancet Oncol 2017 ) + PCWG3 criteria.
Results
150 pt were randomized to dct (75 pt), dct-nivo (37 pt) or dct+ipi-nivo (38 pt). Mean age was 66.4 y (39% >70 y), 98% were Caucasian, 99.3% had ECOG 0-1, 88% were metastatic at diagnosis, mean PSA was 157 ng/ml, 88% had Gleason ≥ 8, 31% visceral involvement, and 17% received local therapy to the prostate, with no differences among arms. With a median follow-up of 32.5 mo from ADT, 60% of pt have progressed and 41.3% have died. Safety is described separately. Efficacy results are summarized in the table. Table: 1783P
RECIST 1.1 + PCWG3 | iRECIST 1.1 + PCWG3 | ||||
Dct | Dct→nivo | Dct+ipi→nivo | Dct→nivo | Dct+ipi→nivo | |
PSA < 50% PSA nadir <0.2 Median PSAPFS (mo) | 88% 21.3% 15.0 | 97.3% 27% 17.4 | 76.3% 36.8% 14.2 | - | - |
CR+PR CR+PR+SD | 34.7% 88.0% | 43.2% 81.1% | 44.7% 73.7% | 43.2% 81.1% | 44.7% 73.7% |
Median rPFS (mo) (95%CI) | 29.2 (23-31) | 25.9 (14.2-30) | 23.7 (14.3-39) | 24.8 (18-33) | 27.8 (15.8-39) |
Median cPFS (mo) (95%CI) | 16.2 (12-23) | 14.2 (10-29) | 14.3 (8.4-22) | 23.3 (13.7-30) | 18.6 (8.4-32) |
Median TCRPC (mo) (95%CI) | 10.4 (8.5-12) | 13.7 (8-27) | 12.5 (5-16) | 13.8 (9-26) | 12.5 (45-17) |
Median TSSRE (mo) | 25.8 | NR | NR | - | - |
Median OS (mo) (95%CI) 18-mo OS HR vs Dx (95%CI) | 32.1 (28-39) 88.4% - | 29.5 (19-NR) 76.2% 1.3 (0.7-2.4) | 30.4 (25-38) 76.5% 1.2 (0.7-2.2) | - | - |
Conclusions
The addition of ipi and/or nivo to ADT + Dct in pt with hvHSPCa is feasible. So far, we have found no statistical or clinically meaningful differences between arms that justify the continuation of the study. Results seem to be similar regardless of using PCWG3 plus either RECIST or iRECIST criteria although some differences between both methods may appear with longer follow-up.
Clinical trial identification
EudraCT 2017-004377-13.
Editorial acknowledgement
Legal entity responsible for the study
SOGUG (Spanish Genitourynary Oncology Group).
Funding
BMS.
Disclosure
J.A. Arranz Arija: Non-Financial Interests, Institutional, Funding, SOGUG: BMS; Financial Interests, Personal, Advisory Board: BMS, Astellas, Pfizer, Novartis, Bayer, AstraZeneca, Ipsen, EUSA; Financial Interests, Personal, Invited Speaker: Merck. J.M. Piulats Rodriguez: Financial Interests, Personal, Advisory Board: Janssen, Astellas, Roche, BMS, MSD, BeiGene, VCN, AstraZeneca; Financial Interests, Personal and Institutional, Research Grant: BMS, Pfizer, Janssen, BeiGene, Mirati. T. Alonso Gordoa: Financial Interests, Personal, Advisory Board: Ipsen, Pfizer, Roche, Sanofi, Bayer, Eisai, Novartis Advanced Accelerator Applications, Lilly, BMS, Astellas; Financial Interests, Personal, Invited Speaker: Janssen Cilag; Non-Financial Interests, Project Lead: Pfizer, Ipsen. B. Perez Valderrama: Financial Interests, Personal, Advisory Board: Pfizer, Astellas Pharma, BMS, Ipsen, EUSA Pharma, Merck, MSD, AstraZeneca, AAA; Financial Interests, Personal, Invited Speaker: BMS, Roche, Bayer, EUSA Pharma, MSD, Merck, Pfizer, Janssen, Astellas Pharma, AAA. N. Sala González: Financial Interests, Personal, Advisory Board: BMS, Merck, Pfizer; Financial Interests, Personal, Invited Speaker: Ipsen. M.A. Climent Duran: Financial Interests, Personal, Advisory Board: Roche, BMS, EUSA, Pfizer, Sanofi, Janssen, Astellas, Merck, Ipsen, MSD; Financial Interests, Personal, Invited Speaker: EUSA, Pfizer, Sanofi, Janssen, Astellas, Merck, Ipsen, BMS, Roche, MSD. E. Gallardo Diaz: Financial Interests, Personal, Advisory Board: Sanofi, Janssen, Astellas, Pfizer, Bayer, Roche, Ipsen, Eisai, EUSA Pharma, BMS, AstraZeneca, Merck, Daiichi Sankyo, Techdow, Lilly, Advanced Accelerator Applications, GSK; Financial Interests, Personal, Invited Speaker: Sanofi, Janssen, Astellas, Pfizer, Bayer, Roche, Ipsen, Eisai, EUSA Pharma, BMS, Merck, Daiichi Sankyo, MSD, Menarini, Rovi, Leo Pharma, Boehringer Ingelheim, Advanced Accelerator Applications; Financial Interests, Personal, Expert Testimony: Merck, Novartis, Pfizer; Financial Interests, Institutional, Local PI: Astellas, Medivation, Ipsen, Janssen, Pfizer, Lilly, Pfizer-Merck, MSD, BMS, Bayer, Daiichi Sankyo, Roche, AstraZeneca, Novartis, Seattle Genetics, Incyte, Aveo, Exelixis, Immunicum, Mediolanum, Clovis, QED Therapeutics; Non-Financial Interests, Leadership Role, Member of the Board: SOGUG; Non-Financial Interests, Leadership Role, Member of the Board of Thrombosis and Cancer Section: SEOM. A. Rodriguez-Vida: Financial Interests, Personal, Invited Speaker: Roche, BMS, Janssen, AstraZeneca, Ipsen; Financial Interests, Personal, Advisory Board: MSD, Pfizer, Astellas, Bayer, Merck. C. Caballero Diaz: Financial Interests, Personal, Advisory Board: Astellas, Ipsen, Ipsen, Janssen, Pfizer, GSK, GSK, BMS, AstraZeneca; Financial Interests, Personal, Invited Speaker: Astellas, Ipsen, Janssen, Pfizer, Roche, Sanofi, BMS, AstraZeneca. J. Puente: Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Janssen, MSD, Pfizer, Eisai, Ipsen, Roche, BMS, Merck; Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, MSD, Bayer, Pfizer, Eisai, Roche, BMS, Merck; Financial Interests, Institutional, Research Grant: Astellas, Roche, Merck. M.J. Mendez Vidal: Financial Interests, Personal, Advisory Board: BMS, MSD, Novartis, Ipsen, Astellas, Pfizer, Merck, Sanofi, Eisai, Bayer; Financial Interests, Personal, Invited Speaker: BMS, Ipsen, Roche, Astellas, Merck, Bayer; Non-Financial Interests, Other, Travel expenses: Ipsen, BMS. E.M.F. Parra: Financial Interests, Personal, Invited Speaker: Bayer, BMS, Merck; Financial Interests, Personal, Advisory Board: Ipsen. J. García Sanchez: Financial Interests, Personal, Advisory Board: Sanofi, Pfizer, Eisai; Financial Interests, Personal, Invited Speaker: Merck, Takeda, PharmaMar, BMS, Novartis. J. Carles Galceran: Financial Interests, Personal, Advisory Board: Astellas Pharma, AstraZeneca, Bayer, Johnson & Johnson, MSD Oncology, Novartis (AAA), Roche, Sanofi; Financial Interests, Institutional, Local PI: Janssen Cilag International NV, Lilly, S.A, Medimmune, Novartis Farmacéutica, S.A, Sanofi-Aventis, S.A. All other authors have declared no conflicts of interest.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1204TiP - Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Presenter: Neel Belani
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14